Drugs / Propamidine
Propamidine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03274895 Comparator | Aug 2017 → Jun 2021 | Acanthamoeba keratitis | SIFI SpA | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Propamidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03274895 ↗ |
| Known as | M&B 782 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL23013 ↗ |
| Known as | Propamidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL23013 ↗ |
| Modality | Small molecule | — CHEMBL23013 ↗ |
| Route | Topical | “PURPOSE: To compare topical PHMB (polihexanide) 0.02% (0.2 mg/ml)+ propamidine 0.1% (1 mg/ml) with PHMB 0.08% (0.8 mg/ml)+ placebo (PHMB 0.08%) for Acanthamoeba keratitis (AK)...” PMID 37802392 ↗ Oct 2023 |